1. "Martin Tallman"
  2. "2014"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (24)
  3. Book Section (3)
Groups
  1. Adult Leukemia (62)
  2. Center for Hematologic Malignancies (62)
  3. Department of Medicine (62)
  4. Hematologic Malignancies, Division of (62)
  5. GSK Faculty (23)
  6. Human Oncology and Pathogenesis Program (22)

More Groups

People
  1. Martin Tallman (62)
  2. Ross Levine (17)
  3. Eytan Stein (14)
  4. Omar Abdel-Wahab (14)
  5. Raajit Rampal (11)
  6. Jae Park (9)

More People

Years
  1. 2014 (62)
Publications
  1. Blood (25)
  2. British Journal of Haematology (5)
  3. Haematologica (4)
  4. Journal of Clinical Oncology (3)
  5. Acta Haematologica (2)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Elsevier Inc. (5)
  3. John Wiley & Sons (5)
  4. Ferrata Storti Foundation (4)
  5. American Society of Clinical Oncology (3)
  6. Wiley Blackwell (3)

More Publishers

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hairy cell leukemia
    Book Section

    Watts, J. M.; Tallman, M. S.
    In Abutalib, S. A.; Markman, M. (Eds.) Cancer Consult: Expertise for Clinical Practice (2014)

    Fulltext@MSK | Save
  • Management of acute promyelocytic leukemia
    Book Section

    Stein, E. M.; Tallman, M. S.
    In Abutalib, S. A.; Markman, M. (Eds.) Cancer Consult: Expertise for Clinical Practice (2014)

    Fulltext@MSK | Save
  • Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Schiller, G. J.; Tallman, M. S.; Goldberg, S. L.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Larson, R. A.; Russell, N.; Trone, D.; Gammon, G.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)
    Meeting Abstract

    DiPersio, J. F.; Erba, H. P.; Larson, R. A.; Luger, S. M.; Mangan, K. F.; Tallman, M. S.; Brill, J. M.; Vuagniaux, G.; Rouits, E.; Zanna, C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
    Meeting Abstract

    Stein, E.; Tallman, M.; Pollyea, D. A.; Flinn, I. W.; Fathi, A. T.; Stone, R. M.; Levine, R. L.; Agresta, S.; Schenkein, D.; Yang, H.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders
    Meeting Abstract

    Kim, E.; Chung, S. S.; Park, J. H.; Chung, Y. R.; Lito, P.; Feldstein, J.; Hu, W. H.; Beguilin, W.; Monette, S.; Duy, C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Telomere length is associated with specific mutations and mutation classes in patients with acute myeloid leukemia
    Meeting Abstract

    Watts, J. M.; Dumitriu, B.; Hilden, P.; Chen, C.; Rapaport, F.; Kishtagari, A.; Ahn, J.; Devlin, S. M.; Rampal, R. K.; Levine, R. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
    Meeting Abstract

    Walter, R. B.; Othus, M.; Paietta, E. M.; Racevskis, J.; Fernandez, H. F.; Lee, J. W.; Sun, Z. X.; Tallman, M. S.; Patel, J. P.; Gonen, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): Early results of US intergroup trial C10403
    Meeting Abstract

    Stock, W.; Luger, S. M.; Advani, A. S.; Geyer, S.; Harvey, R. C.; Mullighan, C. G.; Willman, C. L.; Malnassy, G.; Parker, E.; Laumann, K. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • The DOT1L inhibitor EPZ-5676: Safety and activity in relapsed/refractory patients with MLL-rearranged leukemia
    Meeting Abstract

    Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Savona, M.; Tibes, R.; Altman, J. K.; Jongen-Lavrencic, M.; DoĢˆhner, H.; Armstrong, S.; Pollock, R. M.; more...
    Blood (2014)

    Fulltext@MSK | Save